Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Brixadi Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Clinician Practice Companion to Address Youth Substance Use

NCT07725289
View directory record Official record
Conditions
Substance Use, Substance-Related Disorders, Adolescent Substance Use, Cannabis Use, Opioid Use Disorder, Drug Overdose, Overdose Prevention, Co-occurring Mental Health Conditions
Interventions
Practice Companion
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 24 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Results available

Evaluation of Long-term Buprenorphine Plasma Exposure

NCT03752528
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Blood sample collection, Urine sample collection
Diagnostic Test
Lead sponsor
Indivior Inc.
Industry
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
11
States / cities
Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Three Opioid Detoxification Treatment Regimens

NCT03678792
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Withdrawal
Interventions
Buprenorphine/naloxone, Morphine, Tramadol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Trial of Adherence App for Buprenorphine Treatment (TAAB) Study

NCT03779997
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Video-based DOT Application
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy

NCT05942313
View directory record Official record
Conditions
Opioid Use Disorder, Pregnancy Related
Interventions
Buprenorphine/ Methadone exposure
Drug
Lead sponsor
Ilana Hull
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Early Phase 1 Interventional

Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal

NCT03489161
View directory record Official record
Conditions
Drug Overdose, Opioid Withdrawal, Opioid-use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial of Integrated Treatment for Pain and Opioid Dependence

NCT00634803
View directory record Official record
Conditions
Opiate Dependence, Chronic Pain
Interventions
CBT, Buprenorphine, Educational Counseling, Physician Management
Behavioral · Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional

Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1

NCT00000320
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine formulation: liquid vs. tablet
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1999
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional

ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD

NCT01381107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

NCT03911739
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

NCT04480554
View directory record Official record
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

NCT01366001
View directory record Official record
Conditions
Cocaine Abuse
Interventions
ALKS 33-BUP, ALKS 33, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide in Participants With Opioid Use Disorder

NCT07420283
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Brenipatide, Placebo, Buprenorphine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Comparing Home, Office, and Telehealth Induction for Medication Assisted Treatment for Opioid Use Disorder

NCT04664062
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Dependence
Interventions
Medication Assisted Treatment
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
16 Years to 89 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Denver, Colorado • Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional

MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence

NCT02778282
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MySafeRx™
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Somerville, Massachusetts • Bennington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)

NCT04278586
View directory record Official record
Conditions
Opioid-use Disorder, Stress Related Disorder, Anxiety, Pain Interference
Interventions
Live-Online M-ROCC, Live-Online Control
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT04139213
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care, oral naltrexone
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Laboratory Model for Heroin Abuse Medications - 8

NCT00000273
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Interventions
opiates
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Not yet recruiting Phase 3 Interventional

An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

NCT07296770
View directory record Official record
Conditions
Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions
TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
Device · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Starting Treatment With Agonist Replacement Therapies (START)

NCT00315341
View directory record Official record
Conditions
Opiate-related Disorders
Interventions
Buprenorphine/naloxone, Methadone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings

NCT03698669
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Treating Opioid Patients' Pain and Sadness (TOPPS), Health Education (HE)
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Fall River, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2

NCT00015041
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1998
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

Rural Expanded Access to OUD Care & Linkage Using Toxicologists for Telehealth Initiated Treatment

NCT05711056
View directory record Official record
Conditions
Opioid Use, Opioid Abuse
Interventions
Sociobehavioral Intervention
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 22, 2026, 5:25 AM EDT